

## Crystal structure and function of the CRISPR-Lon protease

Christophe Rouillon<sup>1,3</sup>, Niels Schneberger<sup>1</sup>, Haotian Chi<sup>2</sup>, Martin F. Peter<sup>1</sup>, Matthias Geyer<sup>1</sup>, Wolfgang Boenigk<sup>3</sup>, Reinhard Seifert<sup>3</sup>, Malcolm F. White<sup>2</sup>, Gregor Hagelueken<sup>1,\*</sup>

<sup>1</sup>Institute of Structural Biology, University of Bonn, Venusberg-Campus 1, 53127 Bonn, Germany, <sup>2</sup>School of Biology, University of St Andrews, North Haugh, St Andrews, KY16 9ST, UK. <sup>3</sup>Center of Advanced European Studies and Research (caesar), Ludwig-Erhard-Allee 2, 53175 Bonn, Germany

\*hagelueken@uni-bonn.de

Type III CRISPR defense systems can orchestrate a complex antiviral response that is initiated by the synthesis of cyclic oligoadenylates (cOAs) upon foreign RNA recognition [1]. These second messenger molecules bind to the CARF (CRISPR associated Rossmann-fold) domains of dedicated effector proteins that interfere with cellular pathways of the host, inducing cell death or a dormant state of the cell that is better suited to avoid propagation of the viral attack [2,3]. Here, we report the crystal structure of CRISPR-Lon, the first cOA activated protease. The protein is a soluble monomer and contains a SAVED domain that accommodates cA<sub>4</sub>. Further, we show that CRISPR-Lon forms a stable complex with the 34 kDa CRISPR-T protein. Upon activation by cA<sub>4</sub>, CRISPR-Lon specifically cleaves CRISPR-T, releasing CRISPR-T<sub>23</sub>, a 23 kDa fragment that is structurally very similar to MazF toxins and is likely a sequence specific nuclease. Our results describe the first cOA activated proteolytic enzyme and provide the first example of a SAVED domain connected to a type III CRISPR defense system. The use of a protease as a means to unleash a fast response against a threat has intriguing parallels to eukaryotic innate immunity.

- [1] Kazlauskienė, M., Kostiuk, G., Venclovas, Č., Tamulaitis, G. & Siksnys, V. A cyclic oligonucleotide signaling pathway in type III CRISPR-Cas systems. *Science* **357**, 605-609 (2017).
- [2] Meeske, A. J., Nakandakari-Higa, S. & Marraffini, L. A. Cas13-induced cellular dormancy prevents the rise of CRISPR-resistant bacteriophage. *Nature* **570**, 241-245 (2019).
- [3] Rostøl, J. T. et al. The Card1 nuclease provides defence during type III CRISPR immunity. *Nature* **590**, 624-629 (2021).